US FDA lifts clinical hold on Novavax's combo COVID-flu shot
Portfolio Pulse from
The U.S. FDA has lifted its clinical hold on Novavax's late-stage trial for its COVID-influenza combo and standalone flu vaccines, allowing the company to proceed with its trials.
November 11, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA has lifted the clinical hold on Novavax's late-stage trial for its COVID-influenza combo and standalone flu vaccines, enabling the company to continue its trials.
The lifting of the clinical hold by the FDA is a significant regulatory milestone for Novavax, allowing them to proceed with their vaccine trials. This development is likely to be viewed positively by investors, as it removes a major hurdle in the development process and could lead to future product approvals and revenue generation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100